- call +1-201-465-4211
- email sales@mrinsights.biz
According to this study, over the next five years the Oncology Biomarker market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Oncology Biomarker business, shared in Chapter 3.
This report presents a comprehensive overview, market shares and growth opportunities of Oncology Biomarker market by product type, application, key companies and key regions.
This study considers the Oncology Biomarker value generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Stomach Cancer
Others
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Diagnostics
Drug Discovery And Development
Prognostics
Risk Assessment
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
F.Hoffmann-La Roche Ltd.
Qiagen N.V.
Bristol-Myers Squibb
Abbott Laboratories
Genomic Health
Eli Lilly and Company
Merck & Co.
GlaxoSmithKline plc
Pfizer
Novartis AG
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Oncology Biomarker market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Oncology Biomarker market by identifying its various subsegments.
Focuses on the key global Oncology Biomarker players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Oncology Biomarker with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Oncology Biomarker submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
2019-2024 Global Oncology Biomarker Market Report (Status and Outlook)
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Oncology Biomarker Market Size 2014-2024
2.1.2 Oncology Biomarker Market Size CAGR by Region
2.2 Oncology Biomarker Segment by Type
2.2.1 Lung Cancer
2.2.2 Lung Cancer
2.2.3 Colorectal Cancer
2.2.4 Prostate Cancer
2.2.5 Stomach Cancer
2.2.6 Others
2.3 Oncology Biomarker Market Size by Type
2.3.1 Global Oncology Biomarker Market Size Market Share by Type (2014-2019)
2.3.2 Global Oncology Biomarker Market Size Growth Rate by Type (2014-2019)
2.4 Oncology Biomarker Segment by Application
2.4.1 Diagnostics
2.4.2 Drug Discovery And Development
2.4.3 Prognostics
2.4.4 Risk Assessment
2.4.5 Others
2.5 Oncology Biomarker Market Size by Application
2.5.1 Global Oncology Biomarker Market Size Market Share by Application (2014-2019)
2.5.2 Global Oncology Biomarker Market Size Growth Rate by Application (2014-2019)
3 Global Oncology Biomarker by Players
3.1 Global Oncology Biomarker Market Size Market Share by Players
3.1.1 Global Oncology Biomarker Market Size by Players (2017-2019)
3.1.2 Global Oncology Biomarker Market Size Market Share by Players (2017-2019)
3.2 Global Oncology Biomarker Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Oncology Biomarker by Regions
4.1 Oncology Biomarker Market Size by Regions
4.2 Americas Oncology Biomarker Market Size Growth
4.3 APAC Oncology Biomarker Market Size Growth
4.4 Europe Oncology Biomarker Market Size Growth
4.5 Middle East & Africa Oncology Biomarker Market Size Growth
5 Americas
5.1 Americas Oncology Biomarker Market Size by Countries
5.2 Americas Oncology Biomarker Market Size by Type
5.3 Americas Oncology Biomarker Market Size by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Oncology Biomarker Market Size by Countries
6.2 APAC Oncology Biomarker Market Size by Type
6.3 APAC Oncology Biomarker Market Size by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries
7 Europe
7.1 Europe Oncology Biomarker by Countries
7.2 Europe Oncology Biomarker Market Size by Type
7.3 Europe Oncology Biomarker Market Size by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Oncology Biomarker by Countries
8.2 Middle East & Africa Oncology Biomarker Market Size by Type
8.3 Middle East & Africa Oncology Biomarker Market Size by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Global Oncology Biomarker Market Forecast
10.1 Global Oncology Biomarker Market Size Forecast (2019-2024)
10.2 Global Oncology Biomarker Forecast by Regions
10.2.1 Global Oncology Biomarker Forecast by Regions (2019-2024)
10.2.2 Americas Market Forecast
10.2.3 APAC Market Forecast
10.2.4 Europe Market Forecast
10.2.5 Middle East & Africa Market Forecast
10.3 Americas Forecast by Countries
10.3.1 United States Market Forecast
10.3.2 Canada Market Forecast
10.3.3 Mexico Market Forecast
10.3.4 Brazil Market Forecast
10.4 APAC Forecast by Countries
10.4.1 China Market Forecast
10.4.2 Japan Market Forecast
10.4.3 Korea Market Forecast
10.4.4 Southeast Asia Market Forecast
10.4.5 India Market Forecast
10.4.6 Australia Market Forecast
10.5 Europe Forecast by Countries
10.5.1 Germany Market Forecast
10.5.2 France Market Forecast
10.5.3 UK Market Forecast
10.5.4 Italy Market Forecast
10.5.5 Russia Market Forecast
10.5.6 Spain Market Forecast
10.6 Middle East & Africa Forecast by Countries
10.6.1 Egypt Market Forecast
10.6.2 South Africa Market Forecast
10.6.3 Israel Market Forecast
10.6.4 Turkey Market Forecast
10.6.5 GCC Countries Market Forecast
10.7 Global Oncology Biomarker Forecast by Type
10.8 Global Oncology Biomarker Forecast by Application
11 Key Players Analysis
11.1 F.Hoffmann-La Roche Ltd.
11.1.1 Company Details
11.1.2 Oncology Biomarker Product Offered
11.1.3 F.Hoffmann-La Roche Ltd. Oncology Biomarker Revenue, Gross Margin and Market Share (2017-2019)
11.1.4 Main Business Overview
11.1.5 F.Hoffmann-La Roche Ltd. News
11.2 Qiagen N.V.
11.2.1 Company Details
11.2.2 Oncology Biomarker Product Offered
11.2.3 Qiagen N.V. Oncology Biomarker Revenue, Gross Margin and Market Share (2017-2019)
11.2.4 Main Business Overview
11.2.5 Qiagen N.V. News
11.3 Bristol-Myers Squibb
11.3.1 Company Details
11.3.2 Oncology Biomarker Product Offered
11.3.3 Bristol-Myers Squibb Oncology Biomarker Revenue, Gross Margin and Market Share (2017-2019)
11.3.4 Main Business Overview
11.3.5 Bristol-Myers Squibb News
11.4 Abbott Laboratories
11.4.1 Company Details
11.4.2 Oncology Biomarker Product Offered
11.4.3 Abbott Laboratories Oncology Biomarker Revenue, Gross Margin and Market Share (2017-2019)
11.4.4 Main Business Overview
11.4.5 Abbott Laboratories News
11.5 Genomic Health
11.5.1 Company Details
11.5.2 Oncology Biomarker Product Offered
11.5.3 Genomic Health Oncology Biomarker Revenue, Gross Margin and Market Share (2017-2019)
11.5.4 Main Business Overview
11.5.5 Genomic Health News
11.6 Eli Lilly and Company
11.6.1 Company Details
11.6.2 Oncology Biomarker Product Offered
11.6.3 Eli Lilly and Company Oncology Biomarker Revenue, Gross Margin and Market Share (2017-2019)
11.6.4 Main Business Overview
11.6.5 Eli Lilly and Company News
11.7 Merck & Co.
11.7.1 Company Details
11.7.2 Oncology Biomarker Product Offered
11.7.3 Merck & Co. Oncology Biomarker Revenue, Gross Margin and Market Share (2017-2019)
11.7.4 Main Business Overview
11.7.5 Merck & Co. News
11.8 GlaxoSmithKline plc
11.8.1 Company Details
11.8.2 Oncology Biomarker Product Offered
11.8.3 GlaxoSmithKline plc Oncology Biomarker Revenue, Gross Margin and Market Share (2017-2019)
11.8.4 Main Business Overview
11.8.5 GlaxoSmithKline plc News
11.9 Pfizer
11.9.1 Company Details
11.9.2 Oncology Biomarker Product Offered
11.9.3 Pfizer Oncology Biomarker Revenue, Gross Margin and Market Share (2017-2019)
11.9.4 Main Business Overview
11.9.5 Pfizer News
11.10 Novartis AG
11.10.1 Company Details
11.10.2 Oncology Biomarker Product Offered
11.10.3 Novartis AG Oncology Biomarker Revenue, Gross Margin and Market Share (2017-2019)
11.10.4 Main Business Overview
11.10.5 Novartis AG News
12 Research Findings and Conclusion
List of Tables and Figures
Table Product Specifications of Oncology Biomarker
Figure Oncology Biomarker Report Years Considered
Figure Market Research Methodology
Figure
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
